14,253 Shares in 2seventy bio, Inc. (NASDAQ:TSVT) Bought by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System bought a new position in 2seventy bio, Inc. (NASDAQ:TSVTGet Rating) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,253 shares of the company’s stock, valued at approximately $188,000.

Several other hedge funds also recently made changes to their positions in TSVT. State Street Corp purchased a new position in shares of 2seventy bio in the first quarter worth $53,909,000. Wellington Management Group LLP purchased a new position in shares of 2seventy bio in the first quarter worth $42,854,000. BlackRock Inc. purchased a new position in shares of 2seventy bio in the first quarter worth $27,189,000. Vanguard Group Inc. purchased a new position in shares of 2seventy bio in the first quarter worth $23,549,000. Finally, RTW Investments LP purchased a new position in shares of 2seventy bio in the first quarter worth $20,975,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TSVT. Canaccord Genuity Group reduced their price objective on shares of 2seventy bio from $42.00 to $28.00 in a research report on Friday, August 12th. SVB Leerink reduced their price objective on shares of 2seventy bio from $42.00 to $41.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 8th. Guggenheim began coverage on shares of 2seventy bio in a research report on Monday, October 31st. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Morgan Stanley boosted their price objective on shares of 2seventy bio from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, November 8th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, 2seventy bio presently has a consensus rating of “Buy” and an average price target of $30.80.

2seventy bio Trading Up 10.0 %

Shares of TSVT stock opened at $15.40 on Wednesday. 2seventy bio, Inc. has a 12 month low of $9.91 and a 12 month high of $34.02. The stock has a market cap of $583.92 million and a PE ratio of -1.62. The company’s fifty day moving average price is $15.05 and its 200-day moving average price is $14.21.

2seventy bio Profile

(Get Rating)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.

Featured Stories

Want to see what other hedge funds are holding TSVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 2seventy bio, Inc. (NASDAQ:TSVTGet Rating).

Institutional Ownership by Quarter for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.